Newsletter 2022
CEO commentsThe year 2022 can be summarized in great progress for Aptahem. We have taken several steps towards to goal to develop our lead candidate Apta-1 for acute, inflammatory diseases such as sepsis. The year was focused on intensive and diligent work to prepare for the First in Human study with our candidate Apta-1 and during the fourth quarter we were able to announce that the study has started. In parallel with the preparation work and initiation of the phase 1 study, we have worked hard with other activities to reach out to the academic and clinical community but also to